Disease · MONDO_0011122

obesity disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. obesity disorder. Diseases, record MONDO_0011122. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011122

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: obesity disorder; Open Targets
Open Targets ID: MONDO_0011122; Open Targets
Other names: Adiposis, Adiposity, Having too much body fat, Obese, Obese (finding), Obesity NOS, Obesity [Ambiguous], Obesity, unspecified, Overweight and obesity, obesity, obesity disease; Open Targets
Disease Ontology: DOID:9970; Disease Ontology
NCI Thesaurus: C3283; NCI Thesaurus
Orphanet: ORPHA:521399; Orphanet
Highest stage of its drugs: Approval, for 34 of its 354 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs354

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SEMAGLUTIDE	CHEMBL2108724	Protein	Approval	EMA Human Drugs and PMDA	146	144	143	Drugs and targets
TIRZEPATIDE	CHEMBL4297839	Protein	Approval	EMA Human Drugs and PMDA	90	88	88	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Approval	EMA Human Drugs	76	73	73	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Approval	EMA Human Drugs	31	29	29	Drugs and targets
PHENTERMINE	CHEMBL1574	Small molecule	Approval	ATC, DailyMed and TTD	37	28	28	Drugs and targets
ORLISTAT	CHEMBL175247	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs and TTD	32	27	27	Drugs and targets
BUPROPION	CHEMBL894	Small molecule	Approval	EMA Human Drugs	29	27	27	Drugs and targets
SIBUTRAMINE	CHEMBL1419	Small molecule	Approval	ATC and TTD	21	19	19	Drugs and targets
SETMELANOTIDE	CHEMBL3301624	Protein	Approval	ATC, EMA Human Drugs and TTD	20	17	17	Drugs and targets
RIMONABANT	CHEMBL111	Small molecule	Approval	ATC and TTD	18	14	14	Drugs and targets

1 to 10 of 354

See all 354 drugs

Targets295

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Monoamine transporter	20	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Monoamine transporter	15	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	12	Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonist	Approval	https://conductscience.org/library/genes/2740	Drugs and targets
CNR1	Cannabinoid receptor 1	8	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor antagonist; Cannabinoid CB1 receptor inverse agonist; Cannabinoid CB1 receptor negative allosteric modulator	Approval	https://conductscience.org/library/genes/1268	Drugs and targets
OPRM1	Mu-type opioid receptor	8	Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
ADRB2	Adrenergic receptor	7	Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor partial agonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
GABRA1	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets

1 to 10 of 295

See all 295 targets

Trials831

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 24 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00603902	BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management	Phase 3	4,008	2013-02-07	Obesity	LORCASERIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01272219	Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes	Phase 3	3,731	2015-02-09	Metabolism and Nutrition Disorder, Obesity	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT00395135	BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management	Phase 3	3,182	2013-02-07	Obesity	LORCASERIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	Phase 3	2,539	2023-04-24	Overweight, Obesity	TIRZEPATIDE	Its record names the disease	ClinicalTrials.gov
NCT00553787	Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions	Phase 3	2,487	2012-09-06	Obesity, Type 2 Diabetes	PHENTERMINE	Its record names the disease	ClinicalTrials.gov
NCT03548935	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	Phase 3	1,961	2021-08-11	Metabolism and Nutrition Disorder, Overweight or Obesity	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT00532779	A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects	Phase 3	1,742	2014-11-21	Obesity, Overweight	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00567255	A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects	Phase 3	1,496	2014-11-21	Obesity, Overweight	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00554216	Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults	Phase 3	1,267	2012-09-06	Obesity	PHENTERMINE	Its record names the disease	ClinicalTrials.gov
NCT03552757	Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity	Phase 3	1,210	2021-08-11	Obesity, Overweight	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 831

See all 831 trials

Comparisons in its trials224

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sema 2.4 mg vs Placebo: deaths from any cause	1 of 1,306	1 of 655	1,961	NCT03548935	Trial comparisons
Sema 2.4 mg vs Placebo: serious adverse events	128 of 1,306	42 of 655	1,961	NCT03548935	Trial comparisons
NB32/48 vs Placebo: serious adverse events	21 of 992	7 of 492	1,484	NCT00567255	Trial comparisons
NB32 vs Placebo: serious adverse events	22 of 584	1 of 200	784	NCT00456521	Trial comparisons
15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: deaths from any cause	0 of 374	0 of 376	750	NCT05822830	Trial comparisons
15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: serious adverse events	18 of 374	13 of 376	750	NCT05822830	Trial comparisons
Tirzepatide - MTD vs Placebo: Number of Participants With Time to All-Cause Death	19 of 364	15 of 367	731	NCT04847557	Trial comparisons
Tirzepatide - MTD vs Placebo: Number of Participants With Time to First Occurrence of HF Events	29 of 364	52 of 367	731	NCT04847557	Trial comparisons
Tirzepatide - MTD vs Placebo: deaths from any cause	19 of 364	15 of 367	731	NCT04847557	Trial comparisons
Tirzepatide - MTD vs Placebo: serious adverse events	96 of 364	94 of 367	731	NCT04847557	Trial comparisons

1 to 10 of 224

See all 224 comparisons in its trials

Papers from its trials561

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42418774	RESULT	1	PubMed
42010357	RESULT	1	PubMed
41944220	RESULT	1	PubMed
41928037	RESULT	1	PubMed
41903163	RESULT	1	PubMed
41666927	RESULT	1	PubMed
41406444	RESULT	1	PubMed
40903131	RESULT	2	PubMed
40691810	RESULT	1	PubMed
39566869	RESULT	2	PubMed

1 to 10 of 561

See all 561 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011122

GET https://conductscience.org/api/diseases/v1/MONDO_0011122/drugs?page=2

API reference For AI assistants